Cannabis. Usos y Aplicaciones en la Práctica Odontológica Diaria
Revisión de la Literatura
Palabras clave:
cannabis, cannabidiol, Tetrahidrocannabinol, receptores de cannabinoides, terapias odontológicasResumen
La evidencia científica presente en la literatura indica que el cannabis puede ser utilizado con fines terapéuticos para tratar distintas afecciones odontológicas. Dado el acceso sencillo a la cavidad bucal, las distintas formulaciones de cannabis pueden aplicarse de forma tópica. La aplicación local de dosis bajas de cannabis ha demostrado alta efectividad para tratar distintas afecciones bucales, constituyendo un tratamiento seguro con baja probabilidad de generar repercusiones sistémicas indeseadas. En la actualidad, está siendo incorporado a materiales convencionales de uso e higiene odontológica con la finalidad de aprovechar sus efectos terapéuticos. El cannabis tiene múltiples usos en odontología: como componente de enjuagues bucales y soluciones para la desinfección de conductos radiculares, en tratamientos de trastornos de ansiedad bucal, como complemento en terapias oncológicas, como analgésico para atenuar el dolor inflamatorio y el neuropático, como miorrelajante y condroprotector para tratar trastornos de articulación témporomandibular (ATM) y bruxismo, como osteomodulador para el tratamiento de patologías que comprometen la integridad ósea, como la enfermedad periodontal y la osteoporosis, y para la cicatrización ósea asociada a fracturas, extracciones dentarias e implantes, y como inmunomodulador con potencial terapéutico para tratar patologías autoinmunes como las enfermedades reumáticas. El tratamiento local con cannabis es efectivo, bien tolerado por el paciente y con pocos efectos adversos. Por lo tanto, se puede concluir que el cannabis aporta un enorme abanico de posibilidades terapéuticas para tratar distintas afecciones odontológicas, aunque aún se requiere mayor cantidad de estudios científicos que avalen su utilización en cada situación fisiopatológica particular.
Citas
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., Etxebarria, N. y Usobiaga, A. (2016). Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. Journal of Natural Products, 79(2), 324–331. https://doi.org/10.1021/acs.jnatprod.5b00949
Alonso Castell, P., Basté Dencàs M. A., Creus Viles, M., Del Pino Gaya, B., Gómez Blasco, C., Gómez Gener, A., Gorgas Torner, M. Q., Muro Perea, N., Pellicer Jacomet, M. A., Sotoca Momblona, J. M., Trullàs Altisen, M. y Vallés Fernández, R. (2001). Prevención y tratamiento de la mucositis en el paciente onco-hematológico. Farmacia Hospitalaria (Madrid), 25(3), 139–149. https://www.elsevier.es/esrevistafarmaciahospitalaria-121-articulo-prevencion-tratamientomucositis-el-paciente-13119084
Atalay, S., Jarocka-Karpowicz, I. y Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel, Switzerland), 9(1), 21. https://doi.org/10.3390/antiox9010021
Becerra Santos, G., Peñaloza-H., A., Cataño, I. C., Gomez, O., Roman, I. D., Escobar, J. F., Valencia, S. y Londoño, P. A. (1995). Terapia oclusal con placas. Revista Facultad de Odontología Universidad de Antioquia, 7(1), 43–49. https://revistas.udea.edu.co/index.php/odont/article/view/27081
Blake, D. R., Robson, P., Ho, M., Jubb, R. W. y McCabe, C. S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford, England), 45(1), 50–52. https://doi.org/10.1093/rheumatology/kei183
Bras, J., van Ooij, C. P., Abraham-Inpijn, L., Kusen, G. J. y Wilmink, J. M. (1982). Radiographic interpretation of the mandibular angular cortex: A diagnostic tool in metabolic bone loss. Part I. Normal state. Oral Surgery, Oral Medicine, and Oral Pathology, 53(5), 541–545. https://doi.org/10.1016/0030-4220(82)90473-x
Caffarel, M. M., Andradas, C., Mira, E., Pérez-Gómez, E., Cerutti, C., Moreno-Bueno, G., Flores, J. M., GarcíaReal, I., Palacios, J., Mañes, S., Guzmán, M. y Sánchez, C. (2010). Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 9, 196. https://doi.org/10.1186/1476-4598-9-196
Chaffee B. W. (2021). Cannabis use and oral health in a national cohort of adults. Journal of the California Dental Association, 49(8), 493–501. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415705/
Clayton, N., Marshall, F. H., Bountra, C. y O’Shaughnessy, C. T. (2002). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96(3), 253–260. https://doi.org/10.1016/S0304-3959(01)00454-7
Cuba, L. F., Salum, F. G., Cherubini, K. y Figueiredo, M. (2017). Cannabidiol: an alternative therapeutic agent for oral mucositis?. Journal of clinical pharmacy and therapeutics, 42(3), 245–250. https://doi.org/10.1111/jcpt.12504
Gaoni, Y. y Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society, 86(8), 1646–
https://doi.org/10.1021/ja01062a046
Gauer, R. L. y Semidey, M. J. (2015). Diagnosis and treatment of temporomandibular disorders. American Family Physician, 91(6), 378–386. https://www.aafp.org/pubs/afp/issues/2015/0315/p378.html
Grotenhermen F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics, 42(4), 327–360. https://doi.org/10.2165/00003088-200342040-00003
Gustafsson, S. B., Lindgren, T., Jonsson, M. y Jacobsson, S. O. (2009). Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemotherapy and Pharmacology, 63(4), 691–701. https://doi.org/10.1007/s00280-008-0788-5
Habib, G., Khazin, F. y Artul, S. (2021). The effect of medical cannabis on pain level and quality of sleep among rheumatology clinic outpatients. Pain Research & Management, 2021, 1756588. https://doi.org/10.1155/2021/1756588
Hampson, A. J., Grimaldi, M., Axelrod, J. y Wink, D. (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8268–8273. https://doi.org/10.1073/pnas.95.14.8268
Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R. y Davidson, E. (2016). The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. The Clinical Journal of Pain, 32(12), 1036–1043. https://doi.org/10.1097/AJP.0000000000000364
Hemp Drugs Commission. India. (1894). Report of the Indian Hemp Drugs Commission, 1893-1894. (v. 1–8). Simla : [Govt. Press]. https://digital.nls.uk/74908458
Idris, A. I., van ‘t Hof, R. J., Greig, I. R., Ridge, S. A., Baker, D., Ross, R. A. y Ralston, S. H. (2005). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine, 11(7), 774–779. https://doi.org/10.1038/nm1255
Kogan, N. M., Melamed, E., Wasserman, E., Raphael, B., Breuer, A., Stok, K. S., Sondergaard, R., Escudero, A. V., Baraghithy, S., Attar-Namdar, M., FriedlanderBarenboim, S., Mathavan, N., Isaksson, H., Mechoulam, R., Müller, R., Bajayo, A., Gabet, Y. y Bab, I. (2015). Cannabidiol, a major non-psychotropic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. Journal of Bone and Mineral Research, 30(10), 1905–1913. https://doi.org/10.1002/jbmr.2513
Kong, Y., Wang, W., Zhang, C., Wu, Y., Liu, Y. y Zhou, X. (2016). Cannabinoid WIN-55,212-2 mesylate inhibits ADAMTS-4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan-1. Molecular Medicine Reports, 13(6), 4569–4576. https://doi.org/10.3892/mmr.2016.5137
Liang, Y. C., Huang, C. C. y Hsu, K. S. (2004). Therapeutic potential of cannabinoids in trigeminal neuralgia. Current drug targets. CNS and Neurological Disorders, 3(6), 507–514. https://doi.org/10.2174/1568007043336833
Lobbezoo, F., Jacobs, R., De Laat, A., Aarab, G., Wetselaar, P. y Manfredini, D. (2017). [Chewing on bruxism. Diagnosis, imaging, epidemiology and aetiology]. Nederlands Tijdschrift voor Tandheelkunde, 124(6), 309–316. https://doi.org/10.5177/ntvt.2017.06.16194
Loza, J. C., Carpio, L. C. y Dziak, R. (1996). Osteoporosis and its relationship to oral bone loss. Current Opinion in Periodontology, 3, 27–33.
Maarbjerg, S., Di Stefano, G., Bendtsen, L. y Cruccu, G. (2017). Trigeminal neuralgia diagnosis and treatment. Cephalalgia, 37(7), 648–657. https://doi.org/10.1177/0333102416687280
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K. A. y Zimmer, A. (2015). Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences, 36(5), 277–296. https://doi.org/10.1016/j.tips.2015.02.008
Mbvundula, E. C., Bunning, R. A. y Rainsford, K. D. (2005). Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochemical Pharmacology, 69(4), 635–640. https://doi.org/10.1016/j.bcp.2004.11.018
McDonough, P., McKenna, J. P., McCreary, C. y Downer, E. J. (2014). Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. The International Journal of Biochemistry & Cell Biology, 55, 72–78. https://doi.org/10.1016/j.biocel.2014.08.007
McPartland J. M. (2008). Expression of the endocannabinoid system in fibroblasts and myofascial tissues. Journal of Bodywork and Movement Therapies, 12(2), 169–182. https://doi.org/10.1016/j.jbmt.2008.01.004
Mechtler, L., Hart, P., Bargnes, V. y Saikali, N. (2019). Medical cannabis treatment in patients with trigeminal neuralgia (P 5.10-020). Neurology, 92(15 Supp), P5.10-020.
Melas, P. A., Scherma, M., Fratta, W., Cifani, C. y Fadda, P. (2021). Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research. International Journal of Molecular Sciences, 22(4), 1863. https://doi.org/10.3390/ijms22041863
Montero, P. H., y Patel, S. G. (2015). Cancer of the oral cavity. Surgical Oncology Clinics of North America, 24(3), 491–508. https://doi.org/10.1016/j.soc.2015.03.006
Morrison, E. E., Sandilands, E. A. y Webb, D. J. (2017). Gabapentin and pregabalin: do the benefits outweigh the harms?. The Journal of the Royal College of Physicians of Edinburgh, 47(4), 310–313. https://doi.org/10.4997/JRCPE.2017.402
Moser U. (2021). Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?. BMJ Case Reports, 14(7), e243072. https://doi.org/10.1136/bcr-2021-243072
Naciones Unidas. (1961). Conferencia de las Naciones Unidas para la adopción de una convención única sobre Estupefacientes 24 de enero a 25 de marzo de 1961, Nueva York [en línea]. https://www.un.org/es/conferences/drug/newyork1961
Nitecka-Buchta, A., Nowak-Wachol, A., Wachol, K., Walczyńska-Dragon, K., Olczyk, P., Batoryna, O., Kempa, W. y Baron, S. (2019). Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. Journal of Clinical Medicine, 8(11), 1886. https://doi.org/10.3390/jcm8111886
Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., Mechoulam, R., Zimmer, A. y Bab, I. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences of the United States of America, 103(3), 696–701. https://doi.org/10.1073/pnas.0504187103
Ossola, C. A., Balcarcel, N. B., Astrauskas, J. I., Bozzini, C., Elverdin, J. C. y Fernández-Solari, J. (2019). A new target to ameliorate the damage of periodontal disease: the role of transient receptor potential vanilloid type-1 in contrast to that of specific cannabinoid receptors in rats. Journal of Periodontology, 90(11), 1325–1335. https://doi.org/10.1002/JPER.18-0766
Ossola, C. A., Rodas, J. A., Balcarcel, N. B., Astrauskas, J. I., Elverdin, J. C. y Fernández-Solari, J. (2020). Signs of alveolar bone damage in early stages of periodontitis and its prevention by stimulation of cannabinoid receptor 2. Model in rats. Acta Odontologica Latinoamericana: AOL, 33(2), 143–152. http://www.scielo.org.ar/pdf/aol/v33n2/1852-4834-aol-33-2-143.pdf
Ossola, C. A., Surkin, P. N., Mohn, C. E., Elverdin, J. C. y Fernández-Solari, J. (2016). Anti-inflammatory and osteoprotective effects of cannabinoid-2 receptor agonist HU-308 in a rat model of lipopolysaccharideinduced periodontitis. Journal of Periodontology, 87(6), 725–734. https://doi.org/10.1902/jop.2016.150612
Ossola, C. A., Surkin, P. N., Pugnaloni, A., Mohn, C. E., Elverdin, J. C., y Fernandez-Solari, J. (2012). Longterm treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflammation Research, 61(9), 941–948. https://doi.org/10.1007/s00011-012-0485-z
Passos-Soares, J. S., Vianna, M., Gomes-Filho, I. S., Cruz, S. S., Barreto, M. L., Adan, L. F., Rösing, C. K., Trindade, S. C., Cerqueira, E. y Scannapieco, F. A. (2017). Association between osteoporosis treatment and severe periodontitis in postmenopausal women. Menopause (New York, N.Y.), 24(7), 789–795. https://doi.org/10.1097/GME.0000000000000830
Perdomo Lovera, M. y Chimenos Klistner, E (2003). Síndrome de boca ardiente: actualización. Avances en Odontoestomatología, 19(4), 193–202. https://doi.org/10.4321/S0213-12852003000400005
Pertwee R. G. (2015). Endocannabinoids and their pharmacological actions. Handbook of Experimental Pharmacology, 231, 1–37. https://doi.org/10.1007/978-3-319-20825-1_1
Phan, N. Q., Siepmann, D., Gralow, I. y Ständer, S. (2010). Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology, 8(2), 88–91. https://doi.org/10.1111/j.1610-0387.2009.07213.x
Pomeroy, M., Fennelly, J. J. y Towers, M. (1986). Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology, 17(3), 285–288. https://doi.org/10.1007/BF00256701
Procaccia, S., Lewitus, G. M., Lipson Feder, C., Shapira, A., Berman, P. y Meiri, D. (2022). Cannabis for medical use: versatile plant rather than a single drug. Frontiers in Pharmacology, 13, 894960. https://doi.org/10.3389/fphar.2022.894960
Rock, E. M., Limebeer, C. L. y Parker, L. A. (2018). Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. Psychopharmacology (Berl), 235(11), 3259–3271. https://doi.org/10.1007/s00213-018-5034-1
Scott, K. A., Dalgleish, A. G. y Liu, W. M. (2014). The combination of cannabidiol and Δ9tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Molecular Cancer Therapeutics, 13(12), 2955–2967. https://doi.org/10.1158/1535-7163. MCT-14-0402
Somvanshi, R. K., Zou, S., Kadhim, S., Padania, S., Hsu, E. y Kumar, U. (2022). Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma. Biochimica et Biophysica Acta Molecular Basis of Disease, 1868(3), 166325. https://doi.org/10.1016/j.bbadis.2021.166325
Stahl, V. y Vasudevan, K. (2020). Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation. Cureus, 12(1), e6809. https://doi.org/10.7759/cureus.6809
Starowicz, K. y Finn, D. P. (2017). Cannabinoids and pain: sites and mechanisms of action. Advances in Pharmacology (San Diego, Calif.), 80, 437–475. https://doi.org/10.1016/bs.apha.2017.05.003
Vacas, M. I., Amer, M., Chiarenza, A. P., Luchelli, M. A., Mandalunis, P. M. y Elverdin, J. C. (2008). Influence of submandibulectomy on alveolar bone loss in rats. Journal of Periodontology, 79(6), 1075–1080. https://doi.org/10.1902/jop.2008.070566
Valk, P., Verbakel, S., Vankan, Y., Hol, S., Mancham, S., Ploemacher, R., Mayen, A., Löwenberg, B. y Delwel, R. (1997). Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood, 90(4), 1448–1457. https://doi.org/10.1182/blood.V90.4.1448
van der Zaag, J., Lobbezoo, F., & Naeije, M. (2000). [Dental and pharmacological treatment options for bruxism]. Nederlands Tijdschrift voor Tandheelkunde, 107(7), 289–292.
Vasudevan, K. y Stahl, V. (2020a). CBD-supplemented polishing powder enhances tooth polishing by inhibiting dental plaque bacteria. Journal of International Society of Preventive & Community Dentistry, 10(6), 766–770. https://doi.org/10.4103/jispcd.JISPCD_351_20
Vasudevan, K. y Stahl, V. (2020b). Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. Journal of Cannabis Research, 2(1), 20. https://doi.org/10.1186/s42238-020-00027-z
Velasco, G., Galve-Roperh, I., Sánchez, C., Blázquez, C. y Guzmán, M. (2004). Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 47(3), 315–323. https://doi.org/10.1016/j.neuropharm.2004.04.016
Verty, A. N., Evetts, M. J., Crouch, G. J., McGregor, I. S., Stefanidis, A. y Oldfield, B. J. (2011). The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology, 36(7), 1349–1358. https://doi.org/10.1038/npp.2011.19
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č. y Prostran, M. (2018). Cannabinoids and pain: new insights from old molecules. Frontiers in Pharmacology, 9, 1259. https://doi.org/10.3389/fphar.2018.01259
Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S. y Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain, 14(2), 136–148. https://doi.org/10.1016/j.jpain.2012.10.009
Yoshida, R., Ohkuri, T., Jyotaki, M., Yasuo, T., Horio, N., Yasumatsu, K., Sanematsu, K., Shigemura, N., Yamamoto, T., Margolskee, R. F., y Ninomiya, Y. (2010). Endocannabinoids selectively enhance sweet taste. Proceedings of the National Academy of Sciences of the United States of America, 107(2), 935–939. https://doi.org/10.1073/pnas.0912048107
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
